清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

伦瓦提尼 医学 彭布罗利珠单抗 肝细胞癌 内科学 肿瘤科 索拉非尼 癌症 免疫疗法
作者
R.S. Finn,Masatoshi Kudo,Philippe Merle,Tim Meyer,S. Qin,M. Ikeda,Run-Nan Xu,Julien Edeline,B-Y. Ryoo,Z. Ren,Ann‐Lii Cheng,P.R. Galle,S. Kaneko,H. Kumada,A. Wang,K. Mody,L. Dubrovsky,A.B. Siegel,J. Llovet
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:33: S1401-S1401 被引量:172
标识
DOI:10.1016/j.annonc.2022.08.031
摘要

The global, randomized, double-blind, Ph3 LEAP-002 study (NCT03713593) evaluated the efficacy and safety of lenvatinib + pembrolizumab (lenva + pembro) vs lenvatinib (lenva) + placebo as 1L therapy for aHCC. Eligible pts with aHCC were randomized 1:1 to lenva (8 mg/day if BW<60 kg or 12 mg/day if BW≥60 kg) plus pembro (200 mg IV Q3W) or lenva plus placebo. Dual primary endpoints OS and PFS (per RECIST 1.1 by BICR) were assessed using the stratified log-rank test. ORR (per RECIST 1.1 by BICR) was a key secondary endpoint. The protocol specified 2 interim analyses (IAs) and a final analysis (FA) for OS. Prespecified efficacy boundaries were one-sided P = 0.002 for PFS at IA1 (prespecified final PFS analysis) and 0.0185 for OS at FA. 794 pts were randomized (lenva + pembro, 395; lenva, 399). At FA (data cutoff 21 June 2022; median follow-up 32.1 mo), 534 OS events had occurred and 36 pts (9.1%) in the lenva + pembro arm and 24 pts (6.1%) in the lenva arm remained on study treatment. The median OS with lenva + pembro was 21.2 mo vs 19.0 mo with lenva, and the HR was 0.840 (95% CI: 0.708-0.997, P=0.0227, Table). HR for PFS at IA1 (data cutoff 5 April 2021) was 0.867 (95% CI: 0.734-1.024, P=0.0466, Table). ORR at FA was 26.1% for lenva + pembro vs 17.5% for lenva. Grade 3-5 treatment-related adverse events (TRAEs) were 62.5% in the lenva + pembro arm and 57.5% in the lenva arm (grade 5 TRAEs, 1.0% vs 0.8%). Post-study systemic anti-cancer treatments were used in 44.1% vs 52.1% of pts, in each arm, respectively.Table: LBA34Lenva + Pembro (N=395)Lenva (N=399)OS at FAMedian (95% CI), mo21.2 (19.0-23.6)19.0 (17.2-21.7) HR (95% CI), P0.840 (0.708-0.997), P=0.0227PFS at IA1Median (95% CI), mo8.2 (6.4-8.4)8.0 (6.3-8.2) HR (95% CI), P0.867 (0.734-1.024), P=0.0466PFS at FAMedian (95% CI), mo8.2 (6.3-8.3)8.1 (6.3-8.3) HR (95% CI)0.834 (0.712-0.978)ORR at FA% (95% CI)26.1 (21.8-30.7)17.5 (13.9-21.6) Open table in a new tab LEAP-002 primary endpoints of OS (at FA) and PFS (at IA1) did not meet pre-specified statistical significance. The combination of lenva + pembro achieved the longest median OS ever reported in 1L HCC Ph3 studies (21.2 mo) with no new safety signals observed. The median OS of 19.0 mo with lenva monotherapy supports its role as a standard of care in 1L aHCC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yan完成签到,获得积分10
4秒前
美满尔蓝完成签到,获得积分10
5秒前
dianeil发布了新的文献求助10
8秒前
舒适的妍完成签到,获得积分10
8秒前
丰富广缘完成签到,获得积分10
11秒前
求求了给篇文献完成签到,获得积分10
15秒前
温暖友易完成签到,获得积分10
15秒前
2s完成签到,获得积分10
17秒前
17秒前
腼腆的冰安完成签到,获得积分10
19秒前
顺利毛豆完成签到,获得积分10
20秒前
陈微完成签到,获得积分10
20秒前
2s发布了新的文献求助10
22秒前
能毕业就行完成签到,获得积分10
23秒前
单薄飞双完成签到,获得积分10
25秒前
苏苏完成签到,获得积分10
25秒前
张永和完成签到,获得积分10
27秒前
威武的成协完成签到,获得积分10
28秒前
无情捕完成签到,获得积分10
29秒前
科研绿老头完成签到,获得积分10
34秒前
小蘑菇的应助被科研通管家采纳,获得10
36秒前
null的应助被科研通管家采纳,获得10
36秒前
深情安青的应助被科研通管家采纳,获得10
36秒前
null的应助被科研通管家采纳,获得10
36秒前
周新哲完成签到,获得积分10
36秒前
Muth完成签到,获得积分10
38秒前
dingyushu完成签到,获得积分10
38秒前
ZF完成签到,获得积分10
38秒前
WULAVIVA完成签到,获得积分10
40秒前
2dingyushu完成签到,获得积分10
43秒前
仇敌克星完成签到,获得积分10
44秒前
baa完成签到,获得积分10
44秒前
du完成签到,获得积分10
45秒前
zheng完成签到,获得积分10
46秒前
Beto发布了新的文献求助10
47秒前
慢波完成签到,获得积分10
48秒前
9dingyushu完成签到,获得积分10
48秒前
秋风之墩完成签到,获得积分10
49秒前
踏实远山完成签到,获得积分10
49秒前
完美梦之完成签到,获得积分10
49秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834410
捐赠科研通 7782895
什么是DOI,文献DOI怎么找? 3434567
关于科研通互助平台的介绍 2558844
邀请新用户注册赠送积分活动 2481280